This clinical trial is focused on studying a disease called Multiple Myeloma, which is a type of cancer that affects the blood. The study will explore the effectiveness of different treatment combinations. One group of participants will receive a combination of medications: Bortezomib, Lenalidomide, and Dexamethasone, followed by a special therapy called Ciltacabtagene Autoleucel, which is a type of CAR-T cell therapy. CAR-T cell therapy is a treatment where a patient’s own immune cells are modified to better fight cancer. The other group will receive the same initial combination of Bortezomib, Lenalidomide, and Dexamethasone, followed by continued treatment with Lenalidomide and Dexamethasone.
The purpose of this study is to compare how well these treatment plans work in terms of how long patients live without their disease getting worse, which is known as progression-free survival. Participants in the study will be randomly assigned to one of the two treatment groups. The study will involve taking medications in the form of tablets or capsules, and some treatments will be given through an infusion, which means the medicine is delivered directly into the bloodstream through a vein.
Throughout the study, participants will be monitored regularly to assess their health and the effectiveness of the treatments. The study aims to provide valuable information on the best treatment approach for people with newly diagnosed Multiple Myeloma who are not planning to undergo a stem cell transplant as their initial therapy. The trial will continue for several years to gather comprehensive data on the long-term effects and benefits of the treatments being tested.
Austria 
Belgium 
Czechia 
Denmark 
Finland 
France 
Germany 
Greece 
Hungary 
Ireland 
Norway 
Poland 
Portugal 
Spain 
Sweden 
The Netherlands